PL2641596T3 - Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby - Google Patents

Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby

Info

Publication number: PL2641596T3
Authority: PL; Poland
Prior art keywords: diphenylprop; derivatives; treating liver; liver disorders; disorders
Prior art date: 2009-11-26

Application number

PL13170128T

Other languages

English (en)

Inventor

Raphaël Darteil

Rémy HANF

Dean Hum

Ingrid Dufour

Original Assignee

Genfit

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-11-26

Filing date

2010-11-26

Publication date

2018-10-31

2010-11-26 Application filed by Genfit filed Critical Genfit

2018-10-31 Publication of PL2641596T3 publication Critical patent/PL2641596T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Zoology (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

PL13170128T 2009-11-26 2010-11-26 Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby PL2641596T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP09306146		2009-11-26
EP10787363.0A EP2504005B1 (en)	2009-11-26	2010-11-26	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
EP13170128.6A EP2641596B1 (en)	2009-11-26	2010-11-26	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

Publications (1)

Publication Number	Publication Date
PL2641596T3 true PL2641596T3 (pl)	2018-10-31

Family

ID=43587223

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL13170128T PL2641596T3 (pl)	2009-11-26	2010-11-26	Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby
PL10787363T PL2504005T3 (pl)	2009-11-26	2010-11-26	Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL10787363T PL2504005T3 (pl)	2009-11-26	2010-11-26	Zastosowanie pochodnych 1,3-difenyloprop-2-en-1-onu do leczenia zaburzeń wątroby

Country Status (24)

Country	Link
US (2)	US8772342B2 (pl)
EP (2)	EP2504005B1 (pl)
JP (4)	JP5833016B2 (pl)
KR (2)	KR101962209B1 (pl)
CN (2)	CN102647982B (pl)
AU (1)	AU2010323066B2 (pl)
BR (1)	BR112012012815B8 (pl)
CA (1)	CA2781451C (pl)
CY (2)	CY1116548T1 (pl)
DK (2)	DK2641596T3 (pl)
EA (1)	EA020849B1 (pl)
ES (2)	ES2681794T3 (pl)
HU (1)	HUE039731T2 (pl)
IL (2)	IL219914A (pl)
LT (1)	LT2641596T (pl)
MX (1)	MX2012006062A (pl)
NZ (1)	NZ600439A (pl)
PH (1)	PH12012501054A1 (pl)
PL (2)	PL2641596T3 (pl)
PT (2)	PT2641596T (pl)
SI (2)	SI2641596T1 (pl)
TR (1)	TR201810393T4 (pl)
WO (1)	WO2011064350A1 (pl)
ZA (1)	ZA201204658B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10722575B2 (en)	2009-11-26	2020-07-28	Genfit	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
AU2010323066B2 (en) *	2009-11-26	2014-12-11	Genfit	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9221751B2 (en)	2009-11-26	2015-12-29	Genfit	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
EP2670486B1 (en)	2011-01-31	2016-04-06	Cadila Healthcare Limited	Treatment for lipodystrophy
AU2014206781B2 (en) *	2013-01-18	2018-08-23	Genfit	Methods of treatment of fibrosis and cancers
MY180160A (en)	2013-04-22	2020-11-23	Cadila Healthcare Ltd	A novel composition for nonalcoholic fatty liver disease (nafld)
EP3004053B1 (en)	2013-05-30	2021-03-24	Cadila Healthcare Limited	A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh)	2013-07-05	2015-04-16	Cadila Healthcare Ltd	協同性組成物
IN2013MU02470A (pl)	2013-07-25	2015-06-26	Cadila Healthcare Ltd
IN2013MU02905A (pl)	2013-09-06	2015-07-03	Cadila Healthcare Ltd
RS59426B1 (sr)	2014-06-13	2019-11-29	Inventiva	Ppar jedinjenja za upotrebu u tretmanu fibroznih bolesti
TN2017000344A1 (en) *	2015-02-06	2019-01-16	Intercept Pharmaceuticals Inc	Pharmaceutical compositions for combination therapy
WO2017046181A1 (en) *	2015-09-14	2017-03-23	Genfit	Methods for diagnosing and evaluating non-alcoholic steatohepatitis
WO2017064635A2 (en)	2015-10-14	2017-04-20	Cadila Healthcare Limited	Pyrrole compound, compositions and process for preparation thereof
EP3416629A4 (en) *	2016-02-16	2019-08-07	CoNCERT Pharmaceuticals, Inc.	DEUTERATED GFT-505
US12053445B2 (en)	2016-03-31	2024-08-06	Genfit	Methods of treatment of cholestatic diseases
US11331292B2 (en)	2016-03-31	2022-05-17	Genfit	Methods of treatment of cholestatic diseases
PT3435996T (pt) *	2016-03-31	2025-05-13	Genfit	Elafibranor para utilização no tratamento de colangite biliar primária
FR3056908B1 (fr) *	2016-09-30	2019-04-19	Nashpharm	Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
FR3056909B1 (fr)	2016-09-30	2019-04-19	Nashpharm	Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree
US20180243263A1 (en)	2016-12-09	2018-08-30	Cadila Healthcare Ltd.	Treatment for primary biliary cholangitis
CN110312705B (zh) *	2017-01-22	2021-07-09	苏州科睿思制药有限公司	Gft-505的晶型及其制备方法和用途
MX2019009909A (es)	2017-02-24	2019-10-14	Genfit	Composiciones farmaceuticas para terapia de combinacion.
CN110536683A (zh) *	2017-04-18	2019-12-03	基恩菲特公司	包含PPAR激动剂如伊拉非诺和乙酰CoA羧化酶ACC抑制剂的组合
JP7259850B2 (ja)	2017-11-30	2023-04-18	シチュアンケルン－バイオテックバイオファーマシューティカルカンパニーリミテッド	芳香族化合物、薬学的組成物及びその使用
US12030840B2 (en)	2018-08-03	2024-07-09	Genfit	Elafibranor salts
MX2021003750A (es)	2018-10-11	2021-06-15	Basf As	Compuestos aromaticos y usos farmaceuticos de los mismos.
RU2702003C1 (ru) *	2019-03-18	2019-10-03	Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России)	Антистеатозное средство
CN113677336B (zh)	2019-04-10	2024-04-30	基恩菲特公司	包含式(i)化合物和glp-1受体激动剂的组合疗法
CN110143890B (zh) *	2019-06-12	2020-12-22	天津科技大学	一种查尔酮衍生物和合成方法及其在制备抗非酒精性脂肪肝炎药物中的应用
CN110143902B (zh) *	2019-06-12	2021-06-04	天津科技大学	含硒查尔酮衍生物Compound 1和合成方法及在抗非酒精性脂肪肝炎药物中的应用
EP4103546A1 (en)	2020-02-10	2022-12-21	Genfit	Polymorphs of elafibranor
WO2022043367A1 (en)	2020-08-26	2022-03-03	Genfit	Compositions and methods for the treatment of primary biliary cholangitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH04202129A (ja)	1990-11-30	1992-07-22	Terumo Corp	肝障害治療薬
NZ271833A (en) *	1993-08-19	1997-08-22	Warner Lambert Co	Substituted 2(5h)-furanone (or thiophenone or pyrrolone) derivatives
CA2395191A1 (en)	1999-12-23	2001-06-28	Tedman Ehlers	Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US6608101B1 (en) *	2000-06-20	2003-08-19	Atherogenics, Inc.	1, 3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
KR100567125B1 (ko)	2001-11-01	2006-03-31	주식회사 안지오랩	칼콘 또는 이의 유도체를 함유하는 매트릭스메탈로프로테아제 활성 억제용 약학 조성물
FR2841784B1 (fr)	2002-07-08	2007-03-02		Composition a base de derives de 1,3-diphenylprop-2en-1-one substitues, preparation et utilisations
FR2841900B1 (fr)	2002-07-08	2007-03-02	Genfit S A	Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
FR2857361B1 (fr)	2003-07-08	2005-09-09	Genfit S A	PREPARATION DE DERIVES DE 1,3-DIPHENYPROP-2-¼n-1-one
EA011305B1 (ru) *	2004-01-08	2009-02-27	Жанфит	Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
JP4689331B2 (ja)	2005-04-19	2011-05-25	三菱電機株式会社	撮像装置
FR2902789A1 (fr)	2006-06-21	2007-12-28	Genfit Sa	Derives de 1,3-diphenylpropane substitues, preparations et utilisations
DE102006062264A1 (de)	2006-12-22	2008-06-26	Joh. Barth & Sohn Gmbh & Co. Kg	Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
AU2010323066B2 (en)	2009-11-26	2014-12-11	Genfit	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders

2010
- 2010-11-26 AU AU2010323066A patent/AU2010323066B2/en active Active
- 2010-11-26 ES ES13170128.6T patent/ES2681794T3/es active Active
- 2010-11-26 US US13/511,170 patent/US8772342B2/en active Active
- 2010-11-26 DK DK13170128.6T patent/DK2641596T3/en active
- 2010-11-26 HU HUE13170128A patent/HUE039731T2/hu unknown
- 2010-11-26 SI SI201031723T patent/SI2641596T1/sl unknown
- 2010-11-26 ES ES10787363.0T patent/ES2441665T3/es active Active
- 2010-11-26 DK DK10787363.0T patent/DK2504005T3/da active
- 2010-11-26 CA CA2781451A patent/CA2781451C/en active Active
- 2010-11-26 PT PT131701286T patent/PT2641596T/pt unknown
- 2010-11-26 PT PT107873630T patent/PT2504005E/pt unknown
- 2010-11-26 BR BR112012012815A patent/BR112012012815B8/pt active IP Right Grant
- 2010-11-26 CN CN201080053762.8A patent/CN102647982B/zh active Active
- 2010-11-26 JP JP2012540447A patent/JP5833016B2/ja active Active
- 2010-11-26 CN CN201410458131.4A patent/CN104434891B/zh active Active
- 2010-11-26 PL PL13170128T patent/PL2641596T3/pl unknown
- 2010-11-26 PL PL10787363T patent/PL2504005T3/pl unknown
- 2010-11-26 WO PCT/EP2010/068346 patent/WO2011064350A1/en not_active Ceased
- 2010-11-26 KR KR1020187008005A patent/KR101962209B1/ko active Active
- 2010-11-26 SI SI201030472T patent/SI2504005T1/sl unknown
- 2010-11-26 MX MX2012006062A patent/MX2012006062A/es active IP Right Grant
- 2010-11-26 LT LTEP13170128.6T patent/LT2641596T/lt unknown
- 2010-11-26 TR TR2018/10393T patent/TR201810393T4/tr unknown
- 2010-11-26 EP EP10787363.0A patent/EP2504005B1/en active Active
- 2010-11-26 PH PH1/2012/501054A patent/PH12012501054A1/en unknown
- 2010-11-26 EA EA201290389A patent/EA020849B1/ru not_active IP Right Cessation
- 2010-11-26 KR KR1020127016566A patent/KR101865677B1/ko active Active
- 2010-11-26 NZ NZ600439A patent/NZ600439A/en unknown
- 2010-11-26 EP EP13170128.6A patent/EP2641596B1/en active Active
2012
- 2012-05-21 IL IL219914A patent/IL219914A/en active IP Right Grant
- 2012-06-22 ZA ZA2012/04658A patent/ZA201204658B/en unknown
2014
- 2014-01-07 CY CY20141100010T patent/CY1116548T1/el unknown
- 2014-05-28 US US14/288,482 patent/US8895619B2/en active Active
2015
- 2015-09-21 IL IL241791A patent/IL241791A0/en active IP Right Grant
- 2015-10-28 JP JP2015212306A patent/JP2016074670A/ja active Pending
2017
- 2017-12-14 JP JP2017239237A patent/JP6594400B2/ja active Active
2018
- 2018-07-20 CY CY20181100759T patent/CY1120444T1/el unknown
2019
- 2019-09-24 JP JP2019173268A patent/JP2020073468A/ja active Pending

Also Published As

Publication number	Publication date
JP5833016B2 (ja)	2015-12-16
US20120252725A1 (en)	2012-10-04
BR112012012815B8 (pt)	2021-05-25
EP2504005B1 (en)	2013-11-06
EA201290389A8 (ru)	2014-05-30
PH12012501054A1 (en)	2014-09-05
KR101865677B1 (ko)	2018-07-16
EP2504005A1 (en)	2012-10-03
CN102647982B (zh)	2014-10-15
NZ600439A (en)	2014-06-27
LT2641596T (lt)	2018-08-10
DK2641596T3 (en)	2018-08-06
US8895619B2 (en)	2014-11-25
JP2016074670A (ja)	2016-05-12
CA2781451A1 (en)	2011-06-03
US8772342B2 (en)	2014-07-08
ES2441665T3 (es)	2014-02-05
PL2504005T3 (pl)	2014-03-31
HUE039731T2 (hu)	2019-01-28
EP2641596A1 (en)	2013-09-25
CY1116548T1 (el)	2017-03-15
JP6594400B2 (ja)	2019-10-23
CN104434891A (zh)	2015-03-25
JP2020073468A (ja)	2020-05-14
CN102647982A (zh)	2012-08-22
IL219914A (en)	2015-10-29
CN104434891B (zh)	2018-03-30
TR201810393T4 (tr)	2018-08-27
BR112012012815B1 (pt)	2021-02-02
AU2010323066B2 (en)	2014-12-11
MX2012006062A (es)	2012-06-28
JP2018070642A (ja)	2018-05-10
JP2013512228A (ja)	2013-04-11
DK2504005T3 (da)	2014-01-13
BR112012012815A8 (pt)	2018-02-27
PT2641596T (pt)	2018-07-31
CA2781451C (en)	2019-04-16
US20140309165A1 (en)	2014-10-16
AU2010323066A1 (en)	2012-06-07
WO2011064350A1 (en)	2011-06-03
BR112012012815A2 (pt)	2017-12-12
EP2641596B1 (en)	2018-05-02
HK1175716A1 (en)	2013-07-12
KR20120101472A (ko)	2012-09-13
CY1120444T1 (el)	2019-07-10
EA020849B1 (ru)	2015-02-27
IL241791A0 (en)	2015-11-30
IL219914A0 (en)	2012-07-31
KR20180031825A (ko)	2018-03-28
ES2681794T3 (es)	2018-09-17
EA201290389A1 (ru)	2013-01-30
SI2504005T1 (sl)	2014-04-30
SI2641596T1 (sl)	2018-09-28
PT2504005E (pt)	2014-01-10
KR101962209B1 (ko)	2019-03-26
ZA201204658B (en)	2013-05-29

Publication	Publication Date	Title
ZA201204658B (en)	2013-05-29	Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
ZA201007127B (en)	2011-12-28	Carboxamide compounds for the treatment of metabolic disorders
SI2229369T1 (sl)	2016-11-30	Derivati 6,7-dialkoksi kinazolina, uporabni za zdravljenje motenj, povezanih z rakom
ZA201001264B (en)	2011-07-27	1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
ZA201107446B (en)	2012-06-27	Compounds for the treatment of metabolic disorders
GB0904285D0 (en)	2009-04-22	Compounds for the treatment of metabolic disorders
GB0904284D0 (en)	2009-04-22	Compounds for the treatment of metabolic disorders
IL210290A0 (en)	2011-03-31	Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
ZA201204391B (en)	2014-11-26	Compounds for the treatment of neurologic disorders
IL209417A0 (en)	2011-01-31	1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
EP2387402A4 (en)	2014-11-12	METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS
IL207906A0 (en)	2010-12-30	Treatment for ocular-related disorders
EP2387565A4 (en)	2012-07-11	2,4-PYRIMIDINDIAMIN COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISEASES
PT2278962E (pt)	2014-04-22	Métodos para o tratamento de desordens dermatológicas
GB2476644B (en)	2012-11-14	1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis
EP2240024A4 (en)	2014-05-21	COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP2349299A4 (en)	2012-03-07	COMPOSITION FOR THE TREATMENT OF HYPERTENSION
GB0904288D0 (en)	2009-04-22	Compounds for the treatment of metabolic disorders
GB0904289D0 (en)	2009-04-22	Compounds for the treatment of metabolic disorders
GB0904290D0 (en)	2009-04-22	Compounds for the treatment of metabolic disorders
GB0904286D0 (en)	2009-04-22	Compounds for the treatment of metabolic disorders
GB0724947D0 (en)	2008-01-30	Composition for the treatment of psychiatric disorders
AU2009905647A0 (en)	2009-12-03	Combination for treating metabolic disorders
HK1163684A (en)	2012-09-14	Compounds for the treatment of metabolic disorders
HK1163686A (en)	2012-09-14	Compounds for the treatment of metabolic disorders